Navigation Links
TPI Reports Fiscal Year 2013 Financial Results
Date:9/27/2013

CHENGDU, China, Sept. 27, 2013 /PRNewswire/ -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the fiscal year 2013.

Fiscal Year 2013 Ended June 30, 2013 Financial Highlights:

  • Revenue was $67.5 million compared with $69.6 million in fiscal year 2012, a decrease of 3.0% year over year;
  • Operating income was $9.3 million, compared with $8.5 million in fiscal year 2012, an increase of 9.0% year over year;
  • Net Income was $6.6 million compared with $6.2 million in fiscal year 2012, an increase of 6.0% year over year;
  • Earnings per share of $0.23 per basic share, $0.23 per diluted share, compared with $0.22 per basic share, or $0.22 per diluted share in fiscal year 2012; 
  • Cash and cash equivalents totaled $26.8 million on June 30, 2013; and
  • Operating cash flow for the fiscal year 2013 ended June 30, 2013 was $8.2 million, compared with operating cash flow of $8.0 million for the fiscal year 2012 ended June 30, 2012.  
  • Comparison of results for the quarters ended June 30, 2013 and 2012:Fiscal YearsEnded June 30,20132012(In millions)Sales$

    67.5$

    69.6Cost of sales$

    41.5$

    45.3Gross profit$

    26.0$

    24.3Total operating expenses$

    16.7$

    15.8Operating income$

    9.3$

    8.5Provision for income taxes$

    2.4$

    2.4Net income$

    6.6$

    6.4Sales for the fiscal year ended June 30, 2013 was $67.5 million, decreased by 3.0% from $69.6 million for the fiscal year 2012, as a result of generic pricing pressure, coupled with prolonged JCM production ramp up. We are currently exploring and implementing various
    '/>"/>

    SOURCE Tianyin Pharmaceutical Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Substantial Reductions of Triglycerides and Apoc-III in Patients with Familial Chylomicronemia
    2. Omeros Reports Initiation of Phase 2 Clinical Trial with OMS824
    3. Isis Reports Follow-Up Data From ISIS-SMN Rx Phase 1 Study In Children With Spinal Muscular Atrophy
    4. InspireMD Reports Fourth Quarter and Fiscal Year 2013 Results
    5. Apollo Medical Holdings Reports Record Fiscal 2014 Second Quarter Results
    6. Cyberonics Reports Inducement Equity Award Under NASDAQ Listing Rule 5635(c)(4)
    7. Genocea Reports Positive Initial Phase 1/2a Results for GEN-003, its Pioneering Therapeutic Vaccine Candidate for the Treatment of Herpes Simplex Virus-2 (HSV-2), at ICAAC 2013
    8. Omeros Reports Additional Positive Results from OMS824 Program
    9. S&P Capital IQ Initiates Coverage on Epigenomics AG in Standard & Poors Factual Stock Reports
    10. CorMedix Reports Receipt of European Patent Office Decision to Allow Prosl Patent to Proceed in European Union
    11. Market Research Reports: Biologics, Biosimilars, Bioseparation Systems for Biopharmaceutical Markets
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/14/2014)... 14, 2014  Medac Pharma, Inc., a privately ... new molecules and improving the effectiveness of existing ... Administration (FDA) has approved Rasuvo™, a subcutaneous injectable ... rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (pJIA) ... dosage strengths, ranging from 7.5 mg to 30 ...
    (Date:7/14/2014)... , July 14, 2014 Sinovac Biotech Ltd. (NASDAQ: ... , announced today that it will hold its 2014 Annual Meeting ... The meeting will be held at No. 39 Shangdi Xi Road, Haidian ... of July 9, 2014 will be eligible to vote and are invited ... approve the re-election of Weidong Yin , Yuk Lam Lo ...
    (Date:7/14/2014)... PARK, Ill., July 14, 2014  Abbott (NYSE: ... branded generics pharmaceuticals business to Mylan for equity ownership ... existing business and Abbott,s developed ... company. This represents a value of approximately $5.3 billion ... developed markets portion of this business generated approximately $2 ...
    Breaking Medicine Technology:Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 2Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 3Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 4Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 5Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 6Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 7Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 8Sinovac Schedules 2014 Annual Meeting of Shareholders 2Sinovac Schedules 2014 Annual Meeting of Shareholders 3Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 2Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 3Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 4Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 5Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 6Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 7
    ... , LYON, France, Dec. 16 /PRNewswire/ -- ... announced today that it has entered into an exclusive, ... its prophylactic vaccine against Staphylococcus, including Methicillin-Resistant ... for several difficult-to-treat infections in humans, sometimes referred to ...
    ... ANN ARBOR, Mich., Dec. 16 GlaxoSmithKline plc [GSK] (NYSE: ... exclusive licensing agreement in the United States and Canada for ... representing the next advance in the treatment of cold sores. ... virus that causes cold sores, herpes labialis . ...
    Cached Medicine Technology:Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 2Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 3Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 4GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment 2
    (Date:7/14/2014)... Wa (PRWEB) July 14, 2014 Dry eyes, ... of aging anymore. As recent research have pointed out, today’s ... from dry eyes as a result of using laptops ... or daily lives. , Because of this phenomenon, it has ... that will not just cure them from having dry eyes, ...
    (Date:7/14/2014)... Cabin Chiang Mai, Asia’s leading inpatient addiction treatment centre, ... – a free comprehensive aftercare service for clients who ... they live in the world. , The Cabin firmly ... maintain their recovery after successfully completing primary treatment should ... As a chronic disease, addicts in recovery are always ...
    (Date:7/14/2014)... 14, 2014 EurekaMag.com has newly published ... is a contagious liver disease that ranges in ... to a serious, lifelong illness that attacks the liver. ... have chronic Hepatitis C virus infection of which approximately ... research category covers all studies on Hepatitis C ...
    (Date:7/14/2014)... According to the Boost Your Bust book review recently ... want to learn how to increase the size of their breasts ... chapters including:, , Chapter 1 – What Are ... 2 – How Natural Breast Enlargement Works , Chapter ... Chapter 4 – The Groundwork , Chapter ...
    (Date:7/14/2014)... Vaginal Mesh lawsuit claims continue to ... mesh manufacturers in the U.S. District Court, Southern District ... federal complaints are pending against pelvic mesh manufacturers that ... (MDL No. 2325), and C.R. Bard, Inc., (MDL No. ... Mesh lawsuit claims pending, according to statistics from the ...
    Breaking Medicine News(10 mins):Health News:Dry Eye Handbook Review | Taking Care of One’s Vision by Using Natural Methods – Vinamy.com 2Health News:Dry Eye Handbook Review | Taking Care of One’s Vision by Using Natural Methods – Vinamy.com 3Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 2Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 3Health News:EurekaMag.com Publishes 64,900 New Studies on Hepatitis C 2Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 2Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 2Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 4Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 5
    ... Lube Leader Reaches Halfway Point in Campaign to Support American ... Heart Association,s Go Red For Women(TM) Movement, HOUSTON, Feb. ... to its goal of raising $1 million for the,American Heart ... Heart Month are almost in the rear-view mirror, Jiffy,Lube wants ...
    ... according to a study of more than 77,000 vitamin ... risk of developing it. , Our study of supplemental ... show any evidence for a decreased risk of lung ... of the University of Washington, in Seattle. Indeed, increasing ...
    ... and a decision algorithm, rather than standard hospital protocols, ... patients with severe sepsis or septic shock can reduce ... costs all without adverse effects on patients, according to ... possible to customize antibiotic treatment duration in patients with ...
    ... UT Southwestern Medical Center have determined that the level, or ... children with sickle cell anemia who are at an increased ... have also found that a published method used to predict ... , Stroke is a serious but increasingly preventable complication of ...
    ... affected by ... rare diseases, NEW YORK, Feb. ... Day will be launched on Friday 29,February...because it,s a rare day that ... Shire plc at:, http://media.medialink.com/WebNR.aspx?story=34701 ), Collectively, rare diseases aren,t ...
    ... to Reliance on Spill-Proof,Cups, GLENDALE, Calif., Feb. 28 ... Dental Hygienists, Association,(CDHA) today urged parents and caregivers to ... "We all know that sippy cups are a godsend ... "But they need to be used wisely and,properly in ...
    Cached Medicine News:Health News:Jiffy Lube(R) Continues Drive Against Heart Disease with Maintenance Partners for Life Campaign 2Health News:Jiffy Lube(R) Continues Drive Against Heart Disease with Maintenance Partners for Life Campaign 3Health News:Jiffy Lube(R) Continues Drive Against Heart Disease with Maintenance Partners for Life Campaign 4Health News:Certain vitamin supplements may increase lung cancer risk, especially in smokers 2Health News:Customized treatments for sepsis lower treatment time and reduce length of ICU stays 2Health News:UT Southwestern researchers investigate predictors for sickle-cell-anemia complications 2Health News:VIDEO from Medialink and Shire plc: Rare Diseases Must Be Top of the Health Agenda 2Health News:VIDEO from Medialink and Shire plc: Rare Diseases Must Be Top of the Health Agenda 3Health News:California Dental Hygienists Offer Tips for Safe Sippy Cup Use 2
    The ENDO MINI-RETRACT™ 5 mm instrument has application in a variety of gynecologic, abdominal, urologic, thoracic and endoscopic procedures for temporary retraction of tissue and small tubular ...
    The ENDO PEANUT™ instrument has indications in endoscopic surgery for swabbing small amounts of ?uid or for blunt dissection of soft tissue(s) and structures, or as an aid in controlling minor ...
    ... Introducing the widest offering of single-use instruments on ... long 43cm lengths for Bariatric Surgery. , ... Extended insulation covers the pivot points to reduce ... A 4mm universal cord, which eliminates gapping at ...
    SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
    Medicine Products: